Literature DB >> 14610254

Intracerebroventricular administration of insulin and glucose inhibits the anorectic action of leptin in rats.

Naruhiro Fujita1, Hiroyuki Sakamaki, Shigeo Uotani, Ryoko Takahashi, Hironaga Kuwahara, Atsushi Kita, Katsuya Oshima, Hironori Yamasaki, Yoshihiko Yamaguchi, Katsumi Eguchi.   

Abstract

Obese individuals with glucose intolerance present with high serum levels of glucose, insulin, and leptin. These substances are potent inhibitors of feeding in the brain. Obese subjects still present with over-feeding despite elevation of the above factors. To elucidate the mechanism of this paradox, the effects of insulin and glucose on the anorectic action of leptin in the hypothalamus were examined. Adult male Sprague-Dawley rats (weighing 285-320 g) were pretreated with intracerebroventricular injection of insulin, glucose, or saline, followed by leptin (7.5 microg) or phosphate-buffered saline (PBS) injection into the third cerebral ventricle (icv). The cumulative food intakes were measured 24 hr after leptin icv. The tyrosine phosphorylation of signal transducer and activator transcription factor 3 (STAT3) in the hypothalamus was determined by Western blotting. In rats pretreated with saline and stimulated with leptin (saline/LEPTIN group), food intake diminished to about 50% of that of the saline/PBS group (P < 0.005). Food intake in the insulin/LEPTIN group was significantly higher compared with the saline/LEPTIN group (P < 0.005) and reached the level seen in the saline/PBS group. Similar data were obtained in glucose pretreatment experiments. Insulin and glucose icv resulted in reduction of leptin-induced STAT3 tyrosine phosphorylation compared with saline. Infusion of insulin and glucose icv did not alter peripheral blood glucose levels in all groups. High insulin or glucose levels in the brain could result in leptin resistance as manifested by food intake, which is probably due to the attenuation of STAT3 phosphorylation downstream the leptin receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610254     DOI: 10.1177/153537020322801009

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  5 in total

1.  Exercise reduces appetite and traffics excess nutrients away from energetically efficient pathways of lipid deposition during the early stages of weight regain.

Authors:  Amy J Steig; Matthew R Jackman; Erin D Giles; Janine A Higgins; Ginger C Johnson; Chad Mahan; Edward L Melanson; Holly R Wyatt; Robert H Eckel; James O Hill; Paul S MacLean
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-29       Impact factor: 3.619

2.  Gliotransmission and brain glucose sensing: critical role of endozepines.

Authors:  Damien Lanfray; Sébastien Arthaud; Johanne Ouellet; Vincent Compère; Jean-Luc Do Rego; Jérôme Leprince; Benjamin Lefranc; Hélène Castel; Cynthia Bouchard; Boris Monge-Roffarello; Denis Richard; Georges Pelletier; Hubert Vaudry; Marie-Christine Tonon; Fabrice Morin
Journal:  Diabetes       Date:  2012-11-16       Impact factor: 9.461

3.  Diet-induced obesity impairs hypothalamic glucose sensing but not glucose hypothalamic extracellular levels, as measured by microdialysis.

Authors:  I S de Andrade; J C S Zemdegs; A P de Souza; R L H Watanabe; M M Telles; C M O Nascimento; L M Oyama; E B Ribeiro
Journal:  Nutr Diabetes       Date:  2015-06-15       Impact factor: 5.097

4.  The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?

Authors:  Tina Sartorius; Andreas Peter; Martin Heni; Walter Maetzler; Andreas Fritsche; Hans-Ulrich Häring; Anita M Hennige
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

5.  Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain.

Authors:  Michael V Morabito; Yann Ravussin; Bridget R Mueller; Alicja A Skowronski; Kazuhisa Watanabe; Kylie S Foo; Samuel X Lee; Anders Lehmann; Stephan Hjorth; Lori M Zeltser; Charles A LeDuc; Rudolph L Leibel
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.